bpc-157 risks human Dr BPC-157: Experimental Peptide Creates Risk

Available online at: 165

Anthony Vennare, I agree with your take that pharma is unlikely to go after these small molecules (naturally produced, hard to patent, and if you do, it's easy for competitors to make a small change to get around said patent)

Though this in of itself is not conclusive evidence of anything, it has led to an age-related epigenetic drift theory where abnormalities in epigenetic machinery and exposure to certain environmental factors which occur earlier in life lead to aberrant DNA methylation patterns far later, contributing to sporadic Alzheimer's Disease predisposition

Reclassification to Category 1 would allow 503A pharmacies to compound a substance while it remains under FDA evaluation

J.PradinesJ.LamlumH.AzerK.et al

Tirzepatide is a single molecule that activates GLP-1 and GIP receptors, sold as Zepbound and Mounjaro